Drug Profile

Research programme: purinergic P2X7 receptor antagonists - Integral Molecular

Latest Information Update: 02 May 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Integral Molecular
Class Anti-inflammatories; Monoclonal antibodies; Skin disorder therapies; Urologics
Mechanism of Action Purinergic P2X7 receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

02 May 2024 Early research development for Atopic dermatitis, Autoimmune disorders and Glomerulonephritis is ongoing in the US (Integral Molecular pipeline, April 2024)
13 Jan 2020 Research programme: purinoceptor P2X7 antagonits - Integral Molecular is available for licensing as of 13 Jan 2020. https://www.integralmolecular.com/partnering/#antibody
08 Jan 2020 Early research in Atopic dermatitis in USA (Parenteral) before January 2020

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com